Clinical Trial Update: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating nab-sirolimus in patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor
• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Aadi Bioscience, Inc. | Conditions: Neuroendocrine Tumors, NET | Phase 2 | Status: RECRUITING